Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

Nuclear Medicine and Biology

Volumn 34, Issue 2, 2007, Pages 173-183

  Yordanov, Alexander T ^a   Hens, Marc ^a   Pegram, Charles ^a   Bigner, Darell D ^a   Zalutsky, Michael R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1B4M; Lu 177; MeO DOTA; NHS DOTA; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; CHIMERIC ANTIBODY; LIGAND; LUTETIUM 177; MACROCYCLIC COMPOUND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 81C6; MONOCLONAL ANTIBODY 81C6 I 125; PENTETIC ACID; TENASCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CONJUGATION; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOMA; HYDROCARBONS, ACYCLIC; LUTETIUM; MACROCYCLIC COMPOUNDS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TENASCIN; TISSUE DISTRIBUTION;

EID: 33847000874     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.11.003     Document Type: Article

References (46)

1. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., and Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43 (1983) 2796-2805
2. Howeedy A.A., Virtanen I., Laitinen L., Gould N.S., Koukoulis G.K., and Gould V.E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 63 (1990) 798-806
3. Mackie E.J., Chiquet-Ehrismann R., Pearson C.A., Inaguma Y., Taya K., Kawarada Y., et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci U S A 84 (1987) 4621-4625
4. 2 - a preliminary report. J Neuro-Oncol 24 (1995) 109-122
5. Bigner D.D., Brown M.T., Friedman A.H., Coleman R.E., Akabani G., Friedman H.S., et al. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 16 (1998) 2202-2212
6. 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communications: phase I trial results. Clin Cancer Res 2 (1996) 963-972
7. Cokgor I., Akabani G., Kuan C.T., Friedman H.S., Friedman A.H., Coleman R., et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18 (2000) 3862-3872
8. 131I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20 (2002) 1389-1397
9. 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin's lymphoma. Blood 104 (2004) 642-648
10. Akabani G., Reardon D.A., Coleman R.E., Wong T.Z., Metzler S.D., Bowsher J.E., et al. Dosimetry and radiographic analysis of iodine-131-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients: a phase II study. J Nucl Med 46 (2005) 1042-1051
11. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma. Clin Cancer Res 1 (1995) 1447-1454
12. 177Lu-CC49: a phase I/II study. Gyn Oncol 65 (1996) 94-101
13. Meredith R.F., Partridge E.E., Alvarez R.D., Khazaeli M.B., Plott G., Russell C., et al. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 37 (1996) 1491-1496
14. Durbin P.W. Metabolic characteristics within a chemical family. Health Phys 2 (1960) 225-238
15. 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 18 (2003) 525-533
16. 186Re. J Nucl Med 45 (2003) 327-337
17. 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 11 (2005) 5112-5120
18. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 32 (2005) 264-273
19. 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47 (2006) 1127-1135
20. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29 (2002) 431-442
21. 177Lu. Bioconjug Chem 17 (2006) 485-492
22. Camera L., Kinuya S., Garmestani K., Wu C., Brechbiel M.W., Pai L.H., et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35 (1994) 882-889
23. Roselli M., Milenic D.E., Brechbiel M.W., Mirzadeh S., Pippin C.G., Gansow O.A., et al. In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts. Cancer Biother Radiopharm 14 (1999) 209-220
24. Roselli M., Milenic D.E., Mirzadeh S., Brechbiel M.W., Pippin C.G., Gansow O., et al. Biodistribution studies of indium- and yttrium-labeled mAb B72.3 using DTPA-derived bifunctional chelate. Int J Tumor Targeting 1 (1999) 29-40
25. Zalutsky M.R., Archer G.E., Garg P.K., Batra S.K., and Bigner D.D. Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent. Nucl Med Biol 23 (1996) 449-458
26. Reist C.J., Bigner D.D., and Zalutsky M.R. Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res 4 (1998) 2495-2502
27. He X., Archer G.E., Wikstrand C.J., Morrison S.L., Zalutsky M.R., Bigner D.D., et al. Generation and characterization of a mouse/human chimeric antibody directed against extracellular matrix protein tenascin. J Neuroimmunol 52 (1994) 127-137
28. Murphy-Ullrich J.E., Lightner V.A., Aukhil I., Yan Y.Z., Erickson H.P., and Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 115 (1991) 1127-1136
29. Bourdon M.A., Wikstrand C.J., Furthmayr H., Matthews T.J., and Bigner D.D. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43 (1983) 2796-2805
30. Stetter H., and Frank W. Complex formation with tetraazacycloalkane-N,N′,N″,N″′tetraacetic acids as a function of ring size. Angew Chem 88 (1976) 760
31. n . Acta Cryst C52 (1996) 792-795
32. 90Y radioimmunotherapy. Bioconjug Chem 2 (1991) 187-194
33. Brechbiel M.W., Beitzel M.P., and Gansow O.A. Purification of p-nitrobenzyl C-functionalized diethylenetriamine pentaacetic acids for clinical applications using anion-exchange chromatography. J Chromatogr A 771 (1997) 63-69
34. Dadachova E., Chapell L.L., and Brechbiel M.W. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 26 (1999) 977-982
35. Pippin C.G., Parker T.A., McMurry T.J., and Brechbiel M.W. Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. Bioconjug Chem 3 (1992) 342-344
36. Lindmo T., Boven E., Cuttitta F., Fedorko J., and Bunn Jr. P.A. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72 (1984) 77-89
37. 211At-labeled antibodies for clinical use. J Nucl Med 42 (2001) 1508-1515
38. Schold S.C., Bullard D.E., Bigner S.H., Jones T.R., and Bigner D.D. Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice. J Neurooncol 1 (1983) 5-14
39. 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 47 (2006) 912-918
40. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 29 (2002) 431-442
41. Safavy A., Smith D., Jr C., Bazooband A., and Buchsbaum D.J. De novo synthesis of a new diethylenetriaminepentaacetic acid (DTPA) bifunctional chelating agent. Bioconjug Chem 13 (2002) 317-326
42. Safavy A., Smith Jr. D.C., Bazooband A., and Buchsbaum D.J. Synthesis of the first diethylenetriaminepentahydroxamic acid (DTPH) bifunctional chelating agent. Bioconjug Chem 13 (2002) 327-332
43. Stimmel J.B., and Kull Jr. F.C. Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 25 (1998) 117-125
44. Lukes I., Kotek J., Vojtisek P., and Hermann P. Complexes of tetraazacycles bearing methylphosphinic/phosphonic acid pendant arms with copper(II), zinc(II) and lanthanides(III). Coord Chem Rev 16,217 (2001) 287-312
45. Li W.P., Ma D.S., Higginbotham C., Hoffman T., Ketring A.R., Cutler C.S., et al. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 28 (2001) 145-154
46. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 (2001) 1537-1540